drugset / Trial / NCT06060704
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
NaSingle-groupOpen-labelTreatment
Summary
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or intolerant to standard therapy.
Timeline
- Start
- 2023-11
- Primary completion
- 2025-03
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Envafolimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |